During treatment with PD-1/PD-L1 inhibitors, TIM-3 upregulation may suppress T helper cell type 1 (Th1) cell responses and decrease the expression of cytokines like TNF-α and IFN-γ, leading to drug resistance in cancer patients (61, 93). Here, TNF is linked to cancer.